609 related articles for article (PubMed ID: 28639592)
41. Mycophenolate mofetil and systemic lupus erythematosus: an overview.
Pisoni CN; Karim Y; Cuadrado MJ
Lupus; 2005; 14 Suppl 1():s9-11. PubMed ID: 15803925
[TBL] [Abstract][Full Text] [Related]
42. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.
Houssiau FA
Arthritis Res Ther; 2012 Jan; 14(1):202. PubMed ID: 22293173
[TBL] [Abstract][Full Text] [Related]
43. Systemic lupus erythematosus.
D'Cruz DP; Khamashta MA; Hughes GR
Lancet; 2007 Feb; 369(9561):587-96. PubMed ID: 17307106
[TBL] [Abstract][Full Text] [Related]
44. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.
Groot N; de Graeff N; Marks SD; Brogan P; Avcin T; Bader-Meunier B; Dolezalova P; Feldman BM; Kone-Paut I; Lahdenne P; McCann L; Özen S; Pilkington CA; Ravelli A; Royen-Kerkhof AV; Uziel Y; Vastert BJ; Wulffraat NM; Beresford MW; Kamphuis S
Ann Rheum Dis; 2017 Dec; 76(12):1965-1973. PubMed ID: 28877866
[TBL] [Abstract][Full Text] [Related]
45. [The treatment of lupus nephritis, between consolidated strategies and new therapeutic options: a narrative review].
Fontana F; Alfano G; Cappelli G
G Ital Nefrol; 2021 Aug; 38(4):. PubMed ID: 34469086
[TBL] [Abstract][Full Text] [Related]
46. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
47. What is the ideal duration of maintenance therapy for lupus nephritis?
Yap DYH; Chan TM
Expert Rev Clin Immunol; 2022 May; 18(5):425-427. PubMed ID: 35306959
[No Abstract] [Full Text] [Related]
48. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
[TBL] [Abstract][Full Text] [Related]
49. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
50. Treatment of lupus nephritis.
Dolff S; Berden JH; Bijl M
Expert Rev Clin Immunol; 2010 Nov; 6(6):901-11. PubMed ID: 20979555
[TBL] [Abstract][Full Text] [Related]
51. Pediatric lupus nephritis: more options, more chances?
Vachvanichsanong P; McNeil E
Lupus; 2013 May; 22(6):545-53. PubMed ID: 23629826
[TBL] [Abstract][Full Text] [Related]
52. Which dose of steroids and which cytotoxics for severe lupus?
Lutalo PM; Jordan N; D'Cruz DP
Presse Med; 2014 Jun; 43(6 Pt 2):e157-65. PubMed ID: 24882275
[TBL] [Abstract][Full Text] [Related]
53. Maintenance therapy for lupus nephritis--something old, something new.
Balow JE; Austin HA
N Engl J Med; 2004 Mar; 350(10):1044-6. PubMed ID: 14999117
[No Abstract] [Full Text] [Related]
54. [Lupus nephritis: up-to-date].
Karras A
Rev Med Interne; 2015 Feb; 36(2):98-106. PubMed ID: 25443980
[TBL] [Abstract][Full Text] [Related]
55. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.
Jourde-Chiche N; Costedoat-Chalumeau N; Baumstarck K; Loundou A; Bouillet L; Burtey S; Caudwell V; Chiche L; Couzi L; Daniel L; Deligny C; Dussol B; Faguer S; Gobert P; Gondran G; Huart A; Hummel A; Kalbacher E; Karras A; Lambert M; Le Guern V; Lebourg L; Loubière S; Maillard-Lefebvre H; Maurier F; Pha M; Queyrel V; Remy P; Sarrot-Reynauld F; Verhelst D; Hachulla E; Amoura Z; Daugas E;
Ann Rheum Dis; 2022 Oct; 81(10):1420-1427. PubMed ID: 35725295
[TBL] [Abstract][Full Text] [Related]
56. Neuropsychiatric Systemic Lupus Erythematosus with Cerebral Vasculitis and Lupus Nephritis Successfully Treated with High-dose Glucocorticoids and Mycophenolate Mofetil.
Tanaka S; Kawaguchi T; Kudo R; Kimura M; Rikitake Y; Iwao C; Rikitake M; Iwao K; Aizawa A; Kariya Y; Matsuda M; Miyauchi S; Takajo I; Umekita K
Intern Med; 2022 Oct; 61(20):3131-3135. PubMed ID: 35283391
[TBL] [Abstract][Full Text] [Related]
57. Single-dose rituximab in refractory lupus nephritis.
Kotagiri P; Martin A; Hughes P; Becker G; Nicholls K
Intern Med J; 2016 Aug; 46(8):899-901. PubMed ID: 27242250
[TBL] [Abstract][Full Text] [Related]
58. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
Fu YF; Liu GL
Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
[TBL] [Abstract][Full Text] [Related]
59. Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Hailu GT; Hussen SU; Getachew S; Berha AB
BMC Nephrol; 2022 Jun; 23(1):214. PubMed ID: 35715762
[TBL] [Abstract][Full Text] [Related]
60. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil].
Suszek D; Wielosz E; Majdan M
Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
